NEW YORK (GenomeWeb) – Editas Medicine today announced a collaboration with Adverum Biotechnologies on delivery methods of genome-editing treatments for eye diseases.

Menlo Park, California-based Adverum offers adeno-associated viral vectors and experience in ophthalmology.

"Adverum brings a distinctive technology and experience base," Editas CEO Katrine Bosley said in a statement. "This collaboration aligns highly with our broader, multi-faceted delivery strategy."

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

US Attorney General Jeff Sessions is considering using DNA tests to determine relatedness between adult and child migrants, the Daily Caller reports.

Bloomberg reports that Brainstorm Cell Therapeutics plans to offer a treatment it is developing under the "right to try" law for hundreds of thousands of dollars.

In Nature this week: expansion of disease-resistance genes among long-lived oak trees, and more.

In a proof-of-concept study, researchers report being able to determine age from dried bloodstains, Discover's D-brief blog reports.

Sponsored by
Thermo Fisher Scientific

This webinar will discuss how ultra-highly sensitive and customizable targeted next-generation sequencing panels are applied in inherited disease research.